<DOC>
	<DOCNO>NCT00121056</DOCNO>
	<brief_summary>The purpose study determine Enbrel® Kineret® positive effect subject functionality measure Health Assessment Questionnaire Disability Index ( HAQDI ) .</brief_summary>
	<brief_title>REKinDLE : Registry With Enbrel® Kineret® Database Using Longitudinal Evaluations</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Subjects active rheumatoid arthritis define ACR criterion Able start Enbrel® Kineret® therapy ( per approve product monograph ) within approximately 30 day confirm enrolment Active infection time initiate Enbrel® Kineret® therapy Malignancy basal cell carcinoma skin , situ carcinoma cervix , within past 5 year Known hypersensitivity E. coli derive product Known hypersensitivity Enbrel® component Subjects receive , receive : * Enbrel® previous 30 day ; * Remicade® previous 3 month ; * Humira® previous 3 month ; * Kineret® previous 15 day . Subjects begin Enbrel® therapy , treat prior current treatment use Enbrel® Subjects begin Kineret® therapy , treat prior current treatment use Kineret® Treatment investigational therapy 30 day prior enrolment confirmation Presence significant uncontrolled medical condition , investigator 's opinion , precludes use Enbrel® Sepsis risk septic syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>